Top

11-10-2018 | Pathophysiology | Review | Article

The α-cell in diabetes mellitus

Journal: Nature Reviews Endocrinology

Authors: Jesper Gromada, Pauline Chabosseau, Guy A. Rutter

Publisher: Nature Publishing Group UK

Abstract

Findings from the past 10 years have placed the glucagon-secreting pancreatic α-cell centre stage in the development of diabetes mellitus, a disease affecting almost one in every ten adults worldwide. Glucagon secretion is reduced in patients with type 1 diabetes mellitus, increasing the risk of insulin-induced hypoglycaemia, but is enhanced in type 2 diabetes mellitus, exacerbating the effects of diminished insulin release and action on blood levels of glucose. A better understanding of the mechanisms underlying these changes is therefore an important goal. RNA sequencing reveals that, despite their opposing roles in the control of blood levels of glucose, α-cells and β-cells have remarkably similar patterns of gene expression. This similarity might explain the fairly facile interconversion between these cells and the ability of the α-cell compartment to serve as a source of new β-cells in models of extreme β-cell loss that mimic type 1 diabetes mellitus. Emerging data suggest that GABA might facilitate this interconversion, whereas the amino acid glutamine serves as a liver-derived factor to promote α-cell replication and maintenance of α-cell mass. Here, we survey these developments and their therapeutic implications for patients with diabetes mellitus.

Best, C. H. in Glucagon: Molecular Physiology, Clinical and Therapeutic Implications Ch. 1 (eds Lefebvre, P. J. & Unger, R. H.) 1–6 (Pergamon Press, Oxford, 1972).

Murlin, J. R., Clough, H. D., Gibbs, C. B. F. & Stokes, A. M. Aqueous extracts of the pancreas. 1 Influence on the carbohydrate metabolism of depancreatized animals. J. Biol. Chem. 56, 253–296 (1923).

Sutherland, E. W. & De Duve, C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J. Biol. Chem. 175, 663–674 (1948).PubMed

Muller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D. & Tschop, M. H. The new biology and pharmacology of glucagon. Physiol. Rev. 97, 721–766 (2017).PubMed

Sandoval, D. A. & D’Alessio, D. A. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95, 513–548 (2015).PubMed

Lane, M. A. The cytological characters of the areas of langerhans. Am. J. Anat. 7, 409–422 (1907).

Bonner-Weir, S., Sullivan, B. A. & Weir, G. C. Human islet morphology revisited: human and rodent islets are not so different after all. J. Histochem. Cytochem. 63, 604–612 (2015).PubMedPubMedCentral

Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M. & Unger, R. H. Insulin within islets is a physiologic glucagon release inhibitor. J. Clin. Invest. 74, 2296–2299 (1984).PubMedPubMedCentral

Stagner, J. I. & Samols, E. The vascular order of islet cellular perfusion in the human pancreas. Diabetes 41, 93–97 (1992).PubMed

10.

Pisania, A. et al. Quantitative analysis of cell composition and purity of human pancreatic islet preparations. Lab. Invest. 90, 1661–1675 (2010).PubMedPubMedCentral

11.

Rodriguez-Diaz, R. et al. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. Nat. Med. 17, 888–892 (2011).PubMedPubMedCentral

12.

Cerasi, E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 38, 992–997 (1995).PubMed

13.

Kahn, S. E., Zraika, S., Utzschneider, K. M. & Hull, R. L. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52, 1003–1012 (2009).PubMedPubMedCentral

14.

Butler, A. E. et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102–110 (2003).PubMed

15.

Clark, A. et al. Islet amyloid, increased A-cells, reduced B cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9, 151–159 (1988).PubMed

16.

Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C. & Henquin, J. C. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes. Metab. 10, 32–42 (2008).PubMed

17.

Sakuraba, H. et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45, 85–96 (2002).PubMed

18.

Marselli, L. et al. Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia 57, 362–365 (2014).PubMed

19.

Muller, W. A., Faloona, G. R., Aguilar-Parada, E. & Unger, R. H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283, 109–115 (1970).PubMed

20.

Myers, S. R. et al. Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. Metabolism 40, 66–71 (1991).PubMed

21.

Yu, R. Pancreatic alpha-cell hyperplasia: facts and myths. J. Clin. Endocrinol. Metab. 99, 748–756 (2014).PubMed

22.

Eaton, R. P. Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J. Lipid Res. 14, 312–318 (1973).PubMed

23.

Guettet, C. et al. Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats. Lipids 26, 451–458 (1991).PubMed

24.

Bobe, G., Ametaj, B. N., Young, J. W. & Beitz, D. C. Potential treatment of fatty liver with 14-day subcutaneous injections of glucagon. J. Dairy Sci. 86, 3138–3147 (2003).PubMed

25.

Guettet, C., Mathe, D., Navarro, N. & Lecuyer, B. Effects of chronic glucagon administration on rat lipoprotein composition. Biochim. Biophys. Acta 1005, 233–238 (1989).PubMed

26.

Prip-Buus, C., Pegorier, J. P., Duee, P. H., Kohl, C. & Girard, J. Evidence that the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA is an important site of regulation of hepatic fatty acid oxidation in the fetal and newborn rabbit. Perinatal development and effects of pancreatic hormones in cultured rabbit hepatocytes. Biochem. J. 269, 409–415 (1990).PubMedPubMedCentral

27.

Brown, N. F., Salter, A. M., Fears, R. & Brindley, D. N. Glucagon, cyclic AMP and adrenaline stimulate the degradation of low-density lipoprotein by cultured rat hepatocytes. Biochem. J. 262, 425–429 (1989).PubMedPubMedCentral

28.

Nunez, D. J. & D’Alessio, D. Glucagon receptor as a drug target: a witches’ brew of eye of newt (peptides) and toe of frog (receptors). Diabetes Obes. Metab. 20, 233–237 (2018).PubMed

29.

Han, S. et al. Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice. J. Lipid Res. 54, 2615–2622 (2013).PubMedPubMedCentral

30.

Guan, H. P. et al. Glucagon receptor antagonism induces increased cholesterol absorption. J. Lipid Res. 56, 2183–2195 (2015).PubMedPubMedCentral

31.

Bechmann, L. P. et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 56, 952–964 (2012).PubMed

32.

Damond, N. et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist. eLife 5, 10 (2016).

33.

Holst, J. J. et al. Insulin and glucagon: partners for life. Endocrinology 158, 696–701 (2017).PubMedPubMedCentral

34.

Henquin, J. C. & Rahier, J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 54, 1720–1725 (2011).PubMedPubMedCentral

35.

Stefan, Y. et al. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 8, 694–700 (1982).

36.

Nano, R. et al. Human islet distribution programme for basic research: activity over the last 5 years. Diabetologia 58, 1138–1140 (2015).PubMed

37.

Rahier, J., Goebbels, R. M. & Henquin, J. C. Cellular composition of the human diabetic pancreas. Diabetologia 24, 366–371 (1983).PubMed

38.

Cinti, F. et al. Evidence of beta-cell dedifferentiation in human type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 1044–1054 (2016).PubMed

39.

Gao, T. et al. Pdx1 maintains beta cell identity and function by repressing an alpha cell program. Cell Metab. 19, 259–271 (2014).PubMedPubMedCentral

40.

Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223–1234 (2012).PubMedPubMedCentral

41.

Mezza, T. et al. Beta-cell glucose sensitivity is linked to insulin/glucagon bihormonal cells in nondiabetic humans. J. Clin. Endocrinol. Metab. 101, 470–475 (2016).PubMed

42.

Keenan, H. A. et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59, 2846–2853 (2010).PubMedPubMedCentral

43.

Oram, R. A. et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 57, 187–191 (2014).PubMed

44.

Orci, L. et al. Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc. Natl Acad. Sci. USA 73, 1338–1342 (1976).PubMed

45.

Marchetti, P. et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55, 3262–3272 (2012).PubMed

46.

Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17, 1481–1489 (2011).PubMedPubMedCentral

47.

Cryer, P. E. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes*. Diabetologia 45, 937–948 (2002).PubMed

48.

Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H. & Forsham, P. H. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 182, 171–173 (1973).PubMed

49.

Bolli, G. et al. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32, 134–141 (1983).PubMed

50.

Rutter, G. A., Pullen, T. J., Hodson, D. J. & Martinez-Sanchez, A. Pancreatic beta cell identity, glucose sensing and the control of insulin secretion. Biochem. J. 466, 202–218 (2015).

51.

Ravier, M. A. & Rutter, G. A. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54, 1789–1797 (2005).PubMed

52.

Lamy, C. M. et al. Hypoglycemia-activated GLUT2 neurons of the nucleus tractus solitarius stimulate vagal activity and glucagon secretion. Cell Metab. 19, 527–538 (2014).PubMed

53.

Rorsman, P. & Hellman, B. Voltage-activated currents in guinea pig pancreatic alpha 2 cells. Evidence for Ca²⁺-dependent action potentials. J. Gen. Physiol. 91, 223–242 (1988).PubMed

54.

Berts, A., Gylfe, E. & Hellman, B. Ca²⁺ oscillations in pancreatic islet cells secreting glucagon and somatostatin. Biochem. Biophys. Res. Commun. 208, 644–649 (1995).PubMed

55.

Berts, A., Ball, A., Gylfe, E. & Hellman, B. Suppression of Ca²⁺ oscillations in glucagon-producing alpha 2-cells by insulin/glucose and amino acids. Biochim. Biophys. Acta 1310, 212–216 (1996).PubMed

56.

Nadal, A., Quesada, I. & Soria, B. Homologous and heterologous asynchronicity between identified alpha-, beta- and delta-cells within intact islets of Langerhans in the mouse. J. Physiol. 517, 85–93 (1999).PubMedPubMedCentral

57.

Grapengiesser, E., Gylfe, E. & Hellman, B. Glucose effects on cytoplasmic Ca²⁺ of individual pancreatic beta- cells recorded by two procedures for dual-wavelength fluorometry. Exp. Clin. Endocrinol. 93, 321–327 (1989).PubMed

58.

Heimberg, H. et al. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells. Proc. Natl Acad. Sci. USA 93, 7036–7041 (1996).PubMed

59.

Basco, D. et al. Alpha-cell glucokinase suppresses glucose-regulated glucagon secretion. Nat. Commun. 9, 546–03034 (2018).PubMedPubMedCentral

60.

Heimberg, H., De Vos, A., Pipeleers, D., Thorens, B. & Schuit, F. Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization. J. Biol. Chem. 270, 8971–8975 (1995).PubMed

61.

Benner, C. et al. The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15, 620–615 (2014).PubMedPubMedCentral

62.

Blodgett, D. M. et al. Novel observations from next-generation RNA sequencing of highly purified human adult and fetal islet cell subsets. Diabetes 64, 3172–3181 (2015).PubMedPubMedCentral

63.

Segerstolpe, A. et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab. 24, 593–607 (2016).PubMedPubMedCentral

64.

Sun, G. et al. LKB1 and AMPKα1 are required in pancreatic alpha cells for the normal regulation of glucagon secretion and responses to hypoglycemia. Mol. Metab. 4, 277–286 (2015).PubMedPubMedCentral

65.

Semplici, F. et al. Cell type-specific deletion in mice reveals roles for PAS kinase in insulin and glucagon production. Diabetologia 59, 1938–1947 (2016).PubMedPubMedCentral

66.

Hutton, J. C. et al. Similarities in the stimulus-secretion coupling mechanisms of glucose- and 2-keto acid-induced insulin release. Endocrinology 106, 203–219 (1980).PubMed

67.

Maechler, P. & Wollheim, C. B. Mitochondrial signals in glucose-stimulated insulin secretion in the beta cell. J. Physiol. 529, 49–56 (2000).PubMedPubMedCentral

68.

Del Guerra, S. et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54, 727–735 (2005).PubMed

69.

Sekine, N. et al. Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogease in pancreatic β-cell. Potential role in nutrient sensing. J. Biol. Chem. 269, 4895–4902 (1994).PubMed

70.

Jijakli, H. et al. Relevance of lactate dehydrogenase activity to the control of oxidative glycolysis in pancreatic islet B cells. Arch. Biochem. Biophys. 327, 260–264 (1996).PubMed

71.

Zhao, C., Wilson, C. M., Schuit, F., Halestrap, A. P. & Rutter, G. A. Expression and distribution of lactate/monocarboxylate transporter (MCT) isoforms in pancreatic islets and the exocrine pancreas. Diabetes 50, 361–366 (2001).PubMed

72.

Pullen, T. J., Huising, M. O. & Rutter, G. A. Analysis of purified pancreatic islet beta and alpha cell transcriptomes reveals 11β-hydroxysteroid dehydrogenase (Hsd11b1) as a novel disallowed gene. Front. Genet. 8, 41 (2017).PubMedPubMedCentral

73.

Lemaire, K., Thorrez, L. & Schuit, F. Disallowed and allowed gene expression: two faces of mature islet beta cells. Annu. Rev. Nutr. 36, 45–71 (2016).PubMed

74.

Gromada, J., Franklin, I. & Wollheim, C. B. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28, 84–116 (2007).PubMed

75.

Taborsky, G. J. et al. Autonomic mechanism and defects in the glucagon response to insulin-induced hypoglycaemia. Diabetes Nutr. Metab. 15, 318–322 (2002).PubMed

76.

Maruyama, H., Tominaga, M., Bolli, G., Orci, L. & Unger, R. H. The alpha cell response to glucose change during perfusion of anti-insulin serum in pancreas isolated from normal rats. Diabetologia 28, 836–840 (1985).PubMed

77.

Kawamori, D. et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 9, 350–361 (2009).PubMedPubMedCentral

78.

Briant, L. J. B. et al. Delta-cells and beta-cells are electrically coupled and regulate alpha-cell activity via somatostatin. J. Physiol. 596, 197–215 (2018).PubMed

79.

Elliott, A. D., Ustione, A. & Piston, D. W. Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic alpha-cell by lowering cAMP. Am. J. Physiol. Endocrinol. Metab. 308, E130–E143 (2015).PubMed

80.

Lee, Y. et al. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. Proc. Natl Acad. Sci. USA 111, 13217–13222 (2014).PubMed

81.

Faerch, K. et al. Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes 65, 3473–3481 (2016).PubMed

82.

Sharma, A. et al. Impaired insulin action is associated with increased glucagon concentrations in nondiabetic humans. J. Clin. Endocrinol. Metab. 103, 314–319 (2018).PubMed

83.

Ishihara, H., Maechler, P., Gjinovci, A., Herrera, P. L. & Wollheim, C. B. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat. Cell Biol. 5, 330–335 (2003).PubMed

84.

Nicolson, T. J. et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes 58, 2070–2083 (2009).PubMedPubMedCentral

85.

Li, D. et al. Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR). Proc. Natl Acad. Sci. USA 108, 21063–21068 (2011).PubMed

86.

Sladek, R. et al. A genome-wide assocation study identifies novel risk loci for type 2 diabetes. Nature 445, 881–885 (2007).PubMed

87.

Solomou, A. et al. The zinc transporter Slc30a8/ZnT8 is required in a subpopulation of pancreatic α cells for hypoglycemia-induced glucagon secretion. J. Biol. Chem. 290, 21432–21442 (2015).PubMedPubMedCentral

88.

Solomou, A. et al. Over-expression of Slc30a8/ZnT8 selectively in the mouse alpha cell impairs glucagon release and responses to hypoglycemia. Nutr. Metab. 13, 46–0104 (2016).

89.

da Silva Xavier, G. et al. Pancreatic alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion and counter-regulatory responses to hypoglycaemia in mice. Diabetologia 60, 1043–1050 (2017).PubMedPubMedCentral

90.

da Silva Xavier, G. et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 58, 894–905 (2009).PubMedPubMedCentral

91.

Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536, 41–47 (2016).PubMedPubMedCentral

92.

Rorsman, P. et al. Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature 341, 233–236 (1989).PubMed

93.

Bailey, S. J., Ravier, M. A. & Rutter, G. A. Glucose-dependent regulation of γ-aminobutyric acid (GABA A) receptor expression in mouse pancreatic islet alpha-cells. Diabetes 56, 320–327 (2007).PubMed

94.

Taborsky, G. J. Jr, Ahren, B. & Havel, P. J. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 47, 995–1005 (1998).PubMed

95.

Gasbjerg, L. S. et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides 100, 173–181 (2018).PubMed

96.

Orgaard, A. & Holst, J. J. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia 60, 1731–1739 (2017).PubMedPubMedCentral

97.

Madaan, T., Akhtar, M. & Najmi, A. K. Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur. J. Pharm. Sci. 93, 244–252 (2016).PubMed

98.

Baron, M. et al. A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure. Cell Syst. 3, 346–360 (2016).PubMedPubMedCentral

99.

Muraro, M. J. et al. A single-cell transcriptome atlas of the human pancreas. Cell Syst. 3, 385–394 (2016).PubMedPubMedCentral

100.

Li, J. et al. Single-cell transcriptomes reveal characteristic features of human pancreatic islet cell types. EMBO Rep. 17, 178–187 (2016).PubMed

101.

Xin, Y. et al. RNA sequencing of single human islet cells reveals type 2 diabetes genes. Cell Metab. 24, 608–615 (2016).PubMed

102.

Xin, Y. et al. Use of the Fluidigm C1 platform for RNA sequencing of single mouse pancreatic islet cells. Proc. Natl Acad. Sci. USA 113, 3293–3298 (2016).PubMed

103.

Dominguez, G. G. et al. Gene signature of proliferating human pancreatic alpha-cells. Endocrinology 159, 3177–3186 (2018).

104.

Xin, Y. et al. Pseudotime ordering of single human beta-cells reveals states of insulin production and unfolded protein response. Diabetes 67, 1783–1794 (2018).PubMed

105.

Tritschler, S., Theis, F. J., Lickert, H. & Bottcher, A. Systematic single-cell analysis provides new insights into heterogeneity and plasticity of the pancreas. Mol. Metab. 6, 974–990 (2017).PubMedPubMedCentral

106.

Ziv, O., Glaser, B. & Dor, Y. The plastic pancreas. Dev. Cell 26, 3–7 (2013).PubMed

107.

Adriaenssens, A. E. et al. Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia 59, 2156–2165 (2016).PubMedPubMedCentral

108.

DiGruccio, M. R. et al. Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol. Metab. 5, 449–458 (2016).PubMedPubMedCentral

109.

Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J. & Knop, F. K. Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis. Diabetes 66, 235–240 (2017).PubMed

110.

Longuet, C. et al. Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor. Diabetes 62, 1196–1205 (2013).PubMedPubMedCentral

111.

Solloway, M. J. et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of alpha-cell mass. Cell Rep. 12, 495–510 (2015).PubMed

112.

Dean, E. D. et al. Interrupted glucagon signaling reveals hepatic alpha cell axis and role for L-glutamine in alpha cell proliferation. Cell Metab. 25, 1362–1373 (2017).PubMedPubMedCentral

113.

Kim, J. et al. Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic alpha cell hyperplasia in mice. Cell Metab. 25, 1348–1361 (2017).PubMed

114.

Bozadjieva, N. et al. Loss of mTORC1 signaling alters pancreatic alpha cell mass and impairs glucagon secretion. J. Clin. Invest. 127, 4379–4393 (2017).PubMedPubMedCentral

115.

Sayers, S. R. et al. Proglucagon promoter cre-mediated AMPK deletion in mice increases circulating GLP-1 levels and oral glucose tolerance. PLOS ONE 11, e0149549 (2016).PubMedPubMedCentral

116.

Xiao, X. et al. Endogenous reprogramming of alpha cells into beta cells, induced by viral gene therapy, reverses autoimmune diabetes. Cell Stem Cell 22, 78–90 (2018).PubMed

117.

Chakravarthy, H. et al. Converting adult pancreatic islet alpha cells into beta cells by targeting both Dnmt1 and Arx. Cell Metab. 25, 622–634 (2017).PubMedPubMedCentral

118.

Wilcox, C. L., Terry, N. A., Walp, E. R., Lee, R. A. & May, C. L. Pancreatic alpha-cell specific deletion of mouse Arx leads to alpha-cell identity loss. PLOS ONE 8, e66214 (2013).PubMedPubMedCentral

119.

Courtney, M. et al. The inactivation of Arx in pancreatic alpha-cells triggers their neogenesis and conversion into functional beta-like cells. PLOS Genet. 9, e1003934 (2013).PubMedPubMedCentral

120.

Thorel, F. et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464, 1149–1154 (2010).PubMedPubMedCentral

121.

Lu, J. et al. IGFBP1 increases beta-cell regeneration by promoting alpha- to beta-cell transdifferentiation. EMBO J. 35, 2026–2044 (2016).PubMedPubMedCentral

122.

Ben-Othman, N. et al. Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis. Cell 168, 73–85 (2017).PubMed

123.

Brown, M. L., Andrzejewski, D., Burnside, A. & Schneyer, A. L. Activin enhances alpha- to beta-cell transdifferentiation as a source for beta-cells in male FSTL3 knockout mice. Endocrinology 157, 1043–1054 (2016).PubMed

124.

van der Meulen, T. et al. Artemether does not turn alpha cells into beta cells. Cell Metab. 27, 218–225 (2018).PubMed

125.

Thorel, F. et al. Normal glucagon signaling and beta-cell function after near-total alpha-cell ablation in adult mice. Diabetes 60, 2872–2882 (2011).PubMedPubMedCentral

126.

Ackermann, A. M., Wang, Z., Schug, J., Naji, A. & Kaestner, K. H. Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes. Mol. Metab. 5, 233–244 (2016).PubMedPubMedCentral

127.

Bramswig, N. C. et al. Epigenomic plasticity enables human pancreatic alpha to beta cell reprogramming. J. Clin. Invest. 123, 1275–1284 (2013).PubMedPubMedCentral

128.

Papizan, J. B. et al. Nkx2.2 repressor complex regulates islet beta-cell specification and prevents beta-to-alpha-cell reprogramming. Genes Dev. 25, 2291–2305 (2011).PubMedPubMedCentral

129.

Avrahami, D. et al. Aging-dependent demethylation of regulatory elements correlates with chromatin state and improved beta cell function. Cell Metab. 22, 619–632 (2015).PubMedPubMedCentral

130.

Dhawan, S. et al. DNA methylation directs functional maturation of pancreatic beta cells. J. Clin. Invest. 125, 2851–2860 (2015).PubMedPubMedCentral

131.

Arda, H. E. et al. Age-dependent pancreatic gene regulation reveals mechanisms governing human beta cell function. Cell Metab. 23, 909–920 (2016).PubMedPubMedCentral

132.

Moran, I. et al. Human beta cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab. 16, 435–448 (2012).PubMedPubMedCentral

133.

Wang, Y. J. et al. Single-cell mass cytometry analysis of the human endocrine pancreas. Cell Metab. 24, 616–626 (2016).PubMedPubMedCentral

134.

Sipos, B. et al. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J. Clin. Endocrinol. Metab. 100, E783–E788 (2015).PubMed

135.

Larger, E. et al. Pancreatic alpha-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. Endocrinol. Diabetes Metab. Case Rep. 2016, 16-0081 (2016).PubMedPubMedCentral

136.

Challis, B. G. et al. Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinol. Diabetes Metab. Case Rep. 2015, 150105 (2015).PubMedPubMedCentral

137.

Chambers, A. P. et al. The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab. 25, 927–934 (2017).PubMedPubMedCentral

138.

Traub, S. et al. Pancreatic alpha cell-derived glucagon-related peptides are required for beta cell adaptation and glucose homeostasis. Cell Rep. 18, 3192–3203 (2017).PubMed

139.

Saloman, D. & Meda, P. Heterogeneity and contact-dependent regulation of hormone secretion by individual B cells. Exp. Cell Res. 162, 507–520 (1986).

140.

Pipeleers, D. G. Heterogeneity in pancreatic β-cell population. Diabetes 41, 777–781 (1992).PubMed

141.

Gutierrez, G. D., Gromada, J. & Sussel, L. Heterogeneity of the pancreatic beta cell. Front. Genet. 8, 22 (2017).PubMedPubMedCentral

142.

Hodson, D. J. et al. Lipotoxicity disrupts incretin-regulated human beta cell connectivity. J. Clin. Invest. 123, 4182–4194 (2013).PubMedPubMedCentral

143.

Johnston, N. R. et al. Beta cell hubs dictate pancreatic islet responses to glucose. Cell Metab. 24, 389–401 (2016).PubMedPubMedCentral

144.

Mitchell, R. K. et al. Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell mass. Hum. Mol. Genet. 24, 1390–1399 (2014).PubMedPubMedCentral

145.

Hodson, D. J. et al. ADCY5 couples glucose to insulin secretion in human islets. Diabetes 63, 3009–3021 (2014).PubMedPubMedCentral

146.

Mitchell, R. K. et al. The transcription factor Pax6 is required for pancreatic beta cell identity, glucose-regulated ATP synthesis, and Ca²⁺ dynamics in adult mice. J. Biol. Chem. 292, 8892–8906 (2017).PubMedPubMedCentral

147.

Rutter, G. A. GABA signaling: a route to new pancreatic beta cells. Cell Res. 27, 309–310 (2017).PubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

Abstract

Be confident that your patient care is up to date